Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.49 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.49 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.49 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.49 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.49 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.49 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8129129 | 0.92 | GRIK1 (0.43) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL6993387 | 0.76 | GRIK1 (0.55) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL7001818 | 0.75 | GRIK1 (0.51) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL7002334 | 0.74 | ALDH1A1 (0.41) | — | |
| SCHEMBL7000226 | 0.72 | CHEK1 (0.39) | — | |
| SCHEMBL10680326 | 0.71 | GRIA1 (0.67) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL7001755 | 0.70 | GRIK1 (0.49) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL8139453 | 0.69 | GRIA1 (0.50) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL8040637 | 0.69 | GRIK1 (0.56) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL995544 | 0.68 | GRIK1 (0.56) | GRIK1GRIA1GRIA2GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015437-B1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AG (DE) | 2003-12-03 | — | — | EP | disclosed |
| US-6365736-B1 | TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |